Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „significant“
Suchtreffer
Begriffe & Kennungen
Beromun · 4.3 · Significant hepatic dysfunction, e.g. > 2 x upper limits of normal levels of aspartate aminotransferase, alani
Eintrag öffnenBeromun · 4.3 · Significant renal dysfunction, e.g. nephrotic syndrome, serum creatinine > 150 µmol/l, or creatinine clearance
Eintrag öffnenBeromun · 4.5 · Concurrent administration of agents likely to cause significant hypotension is not recommended (see section 4.
Eintrag öffnenBesremi · 4.5 · Co-administration of pegylated interferon alfa-2b showed no significant interaction with tolbutamide 9 -acetyl
Eintrag öffnenBeyfortus · 4.5 · No interaction studies have been performed. Monoclonal antibodies do not typically have significant interactio
Eintrag öffnenBrinavess · 4.8 · Clinically significant adverse reactions observed in clinical trials included hypotension and ventricular arrh
Eintrag öffnenBrintellix · 4.5 · Alcohol No effect on the pharmacokinetics of vortioxetine or ethanol and no significant impairment, relative t
Eintrag öffnenBrintellix · 4.5 · Alcohol No effect on the pharmacokinetics of vortioxetine or ethanol and no significant impairment, relative t
Eintrag öffnenBrintellix · 4.5 · Anticoagulants and antiplatelet medicinal products No significant effects, relative to placebo, were observed
Eintrag öffnenBrintellix · 4.5 · Anticoagulants and antiplatelet medicinal products No significant effects, relative to placebo, were observed
Eintrag öffnenBrintellix · 4.5 · No pharmacodynamic interactions were observed. No significant impairment, relative to placebo, in cognitive fu
Eintrag öffnenBrukinsa · 4.5 · No clinically significant differences in zanubrutinib pharmacokinetics were observed when co-administered with
Eintrag öffnenBrukinsa · 4.5 · No clinically significant differences in zanubrutinib pharmacokinetics were observed when co-administered with
Eintrag öffnenCalquence · 4.5 · No clinically significant differences in acalabrutinib pharmacokinetics were observed when a 100 mg acalabruti
Eintrag öffnenCapecitabine Accord · 4.5 · Bevacizumab There was no clinically significant effect of bevacizumab on the pharmacokinetic parameters of cap
Eintrag öffnenCapecitabine Accord · 4.5 · Brivudine: a clinically significant interaction between brivudine and fluoropyrimidines (e.g. capecitabine, 5-
Eintrag öffnenCapecitabine Accord · 4.5 · Oxaliplatin No clinically significant differences in exposure to capecitabine or its metabolites, free platinu
Eintrag öffnenCapecitabine Teva · 4.5 · Bevacizumab There was no clinically significant effect of bevacizumab on the pharmacokinetic parameters of cap
Eintrag öffnenCapecitabine Teva · 4.5 · Brivudine A clinically significant interaction between brivudine and fluoropyrimidines (e.g. capecitabine, 5-f
Eintrag öffnenCapecitabine Teva · 4.5 · Oxaliplatin No clinically significant differences in exposure to capecitabine or its metabolites, free platinu
Eintrag öffnen